Sanuwave Health (NASDAQ:SNWV) Issues Earnings Results, Misses Estimates By $0.14 EPS

Sanuwave Health (NASDAQ:SNWV) posted its quarterly earnings results on Thursday. The company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.14), FiscalAI reports. The company had revenue of $13.09 million during the quarter, compared to analyst estimates of $13.23 million.

Sanuwave Health Trading Down 5.4%

Shares of SNWV traded down $1.08 on Thursday, reaching $18.85. The company’s stock had a trading volume of 153,648 shares, compared to its average volume of 59,937. Sanuwave Health has a twelve month low of $18.61 and a twelve month high of $46.58. The stock has a market capitalization of $161.73 million, a PE ratio of -14.50 and a beta of 1.32. The firm has a fifty day moving average of $24.37 and a 200-day moving average of $29.62.

Institutional Trading of Sanuwave Health

Several institutional investors and hedge funds have recently modified their holdings of the stock. Praetorian PR LLC grew its position in Sanuwave Health by 1,436.2% during the fourth quarter. Praetorian PR LLC now owns 265,000 shares of the company’s stock valued at $7,908,000 after buying an additional 247,750 shares during the period. Stifel Financial Corp bought a new stake in Sanuwave Health in the fourth quarter worth about $5,291,000. Geode Capital Management LLC purchased a new position in Sanuwave Health in the second quarter valued at about $5,184,000. Lazard Asset Management LLC bought a new position in shares of Sanuwave Health during the 2nd quarter valued at approximately $738,000. Finally, Jane Street Group LLC bought a new position in shares of Sanuwave Health during the 4th quarter valued at approximately $587,000. 42.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Sanuwave Health in a report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Sanuwave Health currently has an average rating of “Moderate Buy” and a consensus target price of $54.00.

Sanuwave Health Company Profile

Sanuwave Health, Inc is a medical technology company specializing in the development and commercialization of non-invasive acoustic wave therapies designed to stimulate tissue regeneration and accelerate healing. The company’s proprietary Extracorporeal Pulse Activated Technology (EPAT) delivers focused acoustic pressure waves to injured or chronic wound sites, activating the body’s natural repair mechanisms. Sanuwave’s primary therapeutic areas include advanced wound care for diabetic and venous ulcers, as well as orthopedic and musculoskeletal conditions.

The company’s lead product, the dermaPACE® system, holds clearance from the U.S.